Quick Answer
Tarsus Pharmaceuticals, Inc. reported Total Revenue of $451.36 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $451.36M | +146.7% |
| 2024 | $182.95M | +948.6% |
| 2023 | $17.45M | -32.4% |
| 2022 | $25.82M | -54.7% |
| 2021 | $57.03M | — |
| 2020 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $118.70M | +146.7% | +15.6% |
| June 30, 2025 | $102.66M | +151.5% | +31.1% |
| March 31, 2025 | $78.33M | +183.7% | +62.8% |
| September 30, 2024 | $48.12M | +2471.8% | +17.9% |
| June 30, 2024 | $40.81M | — | +47.8% |
| March 31, 2024 | $27.61M | +1004.6% | +1375.9% |
| September 30, 2023 | $1.87M | — | — |
| June 30, 2023 | $0.00 | -100.0% | -100.0% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +146.7% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: